Program
FluMist
Also written as “LAIV”, “Trivalent influenza virus vaccine live, intranasal” and “Cold-adapted influenza vaccine trivalent (CAIV-T)”.
Its studies are mostly in Influenza, Human · Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 100 open or running | phase 4since Sep 9, 2005 | May 27, 2005 | none ahead |
| Changchun BCHT Biotechnology | 11 open or running | phase 4since Apr 16, 2026 | Apr 16, 2026 | none ahead |
Also a collaborator on its studies: Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2005First study: phase 1 study in NeoplasmsNew to AstraZenecaAstraZeneca · NCT00112112 · 20 enrolled · United States
- Aug 1, 2005Phase 3 study in Influenza, HumanAstraZeneca · NCT00125944 · 300 enrolled · United States
- Sep 9, 20052 phase 4 studies in Influenza, HumanAstraZeneca · NCT00192140, NCT00192218
- Sep 12, 20054 phase 3 studiesAstraZeneca · NCT00192491, NCT00192335, NCT00192127 and 1 more
- May 11, 2006Phase 3 study in HealthyAstraZeneca · NCT00325481 · 300 enrolled · United States
- Jun 22, 2006Phase 2 study in Influenza, HumanAstraZeneca · NCT00344305 · 200 enrolled · United States
- Apr 16, 2026Changchun BCHT Biotechnology's first study: phase 4 study in Influenza, HumanNew to Changchun BCHT BiotechnologyChangchun BCHT Biotechnology · NCT07545564 · 200 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A weakened live virus vaccine containing three seasonal influenza reassortants with prophylactic activity against influenza subtypes A and B. The trivalent live-attenuated influenza vaccine (LAIV) contains 2 strains of the influenza subtype A, one for H1N1 and one for H3N2, and one strain of subtype”NCIt, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07545564Influenza, Human · China | 4 | By invitation | Changchun BCHT Biotechnology | Apr 23, 2026 | 200 |
| NCT00344305Influenza, Human · United States | 2 | Completed | AstraZeneca | Jul 1, 2006 | 200 |
| NCT00325481Healthy · United States | 3 | Completed | AstraZeneca | 300 | |
| NCT00192413Influenza, Human · South Africa | 3 | Completed | AstraZeneca | Nov 2002 | 3,009 |
| NCT00192491Influenza, Human | 3 | Completed | AstraZeneca | Sep 2003 | 1,200 |
| NCT00192335Healthy · United States | 3 | Completed | AstraZeneca | 890 | |
| NCT00192218Influenza, Human · United States | 4 | Completed | AstraZeneca | Apr 2005 | 3,022 |
| NCT00192127Influenza, Human · United States | 3 | Completed | AstraZeneca | 300 | |
| NCT00192140Influenza, Human · United States | 4 | Completed | AstraZeneca | Oct 2004 | 345 |
| NCT00125944Influenza, Human · United States | 3 | Completed | AstraZeneca | 300 | |
| NCT00112112Neoplasms · United States | 1 | Completed | AstraZeneca | Mar 1, 2008 | 20 |
How it is read
Names in the registry
- “FluMist”, 9 entries
- “LAIV”, 1 entry
- “Trivalent influenza virus vaccine live, intranasal”, 1 entry
- “Cold-adapted influenza vaccine trivalent (CAIV-T)”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 8 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.